NRIX Nurix Therapeutics, Inc. Insider Trading

Chief Legal Officer Christine Ring sells 28,935 shares of NRIX at $20.06 under 10b5-1 plan; retains 13,579 shares plus 134,398 option holdings.

Christine Ring sold 28,935 shares for $580,505.54 via a pre-arranged 10b5-1 trading plan on 2026-06-25, reducing her non-derivative holdings to 13,579 shares post-transaction. This scheduled transaction occurred at $20.06 per share while the current market price stands at $22.46, placing the trade at -2.7% from the 52-week high of $23.09. Ring maintains derivative holdings of 134,398 option shares, meaning her overall economic exposure to NRIX remains substantial despite the share sale. The company reported revenue of $6,252,000.00 in the latest quarter with net income of -$87,174,000.00, reflecting ongoing unprofitability despite annual revenue growth of +54.0%.

CLO Christine Ring sells 37.6K NRIX shares (-42.5% of holdings) at $17.07 amid unprofitability and 80% quarterly surge

Christine Ring, CLO of Nurix Therapeutics, sold 37,600 shares at $17.07, reducing her holdings by 42.5% from 88,497 to 50,897 shares. The sale occurs within a volatile context: the stock has surged 80.0% over 90 days and 54.6% over 30 days, but remains 24.8% below its 52-week high. Nurix reported a net loss of $86.4M on revenue of $7.9M (latest quarter) and experienced annual revenue contraction of 29.2%, indicating the company remains in a pre-profitable biotech phase. The magnitude of the reduction and timing near a 90-day peak warrant attention to whether this reflects capital redeployment or confidence shifts in the company's trajectory.

CFO van Houte Hans sold 20,000 NRIX shares at $25.22, reducing holdings by 39.2%, as stock rebounds 65.3% in 90 days.

CFO van Houte Hans sold 20,000 shares (39.2% of pre-transaction holdings) at $25.22 on 2024-08-26, leaving him with 31,002 shares. The transaction occurs against a backdrop of significant positive price momentum: the stock has risen 65.3% over the past 90 days and currently trades at $25.69, near its 52-week high of $25.69. However, the company's fundamentals present a mixed picture. While revenue growth of 99.3% year-over-year demonstrates strong business expansion with quarterly revenue of $12.1M, Nurix remains unprofitable with a net loss of $44.5M over its most recent full fiscal year. The sale represents a material reduction in executive stake during a period of stock appreciation, though it occurred at a price point near current market levels rather than at depressed valuations.